Topical treatment of herpes simplex virus infection with enzymatically created siRNA swarm

• Published in: Antiviral therapy Vol. 22; no. 7; pp. 631 - 637
• Main Authors: Paavilainen, Henrik, Lehtinen, Jenni, Romanovskaya, Alesia, Nygårdas, Michaela, Bamford, Dennis H, Poranen, Minna M, Hukkanen, Veijo
• Format: Journal Article
• Language: English
• Published: England 01.01.2017
• ISSN: 1359-6535; 2040-2058
• DOI: 10.3851/IMP3153

Herpes simplex virus (HSV) is a common human pathogen. Despite current antivirals, it causes a significant medical burden. Drug resistant strains exist and they are especially prevalent in immunocompromised patients and in HSV eye infections. New treatment modalities are needed. BALB/c mice were corneally infected with HSV and subsequently treated with a swarm of enzymatically created, Dicer-substrate small interfering RNA (siRNA) molecules that targeted the HSV gene UL29. Two infection models were used, one in which the infection was predominantly peripheral and another in which it spread to the central nervous system. Mouse survival, as well as viral spread, load, latency and peripheral shedding, was studied. The anti-HSV-UL29 siRNA swarm alleviated HSV infection symptoms, inhibited viral shedding and replication and had a favourable effect on mouse survival. Treatment with anti-HSV-UL29 siRNA swarm reduced symptoms and viral spread in HSV infection of mice and also inhibited local viral replication in mouse corneas.